See the DrugPatentWatch profile for jublia
The generic version of Jublia is called efinaconazole [1].
When might generic efinaconazole become available?
The patent expiration dates for Jublia (efinaconazole) are a key factor in the availability of generic versions. According to DrugPatentWatch.com, the earliest expected patent expiry for Jublia is in 2027 [2]. However, the situation can be complex, as multiple patents may cover a drug, and legal challenges can influence market entry timelines for generics [2].
What is Jublia used for?
Jublia is a topical antifungal medication prescribed for the treatment of onychomycosis, which is a fungal infection of the nails [3]. It works by inhibiting the growth of fungi [4].
How does efinaconazole work?
Efinaconazole is an azole antifungal. It functions by inhibiting the enzyme lanosterol 14α-demethylase, which is crucial for ergosterol synthesis in fungal cell membranes. This disruption leads to increased cell membrane permeability and ultimately inhibits fungal growth [4].
What are the potential side effects of efinaconazole?
The most common side effect reported with topical efinaconazole is contact dermatitis, which can include itching, redness, and burning at the application site [3].
Who makes Jublia?
Jublia is manufactured by Valeant Pharmaceuticals, now known as Bausch Health Companies [1].
Are there other treatments for nail fungus?
Besides topical treatments like efinaconazole, other treatment options for nail fungus may include oral antifungal medications, and in some cases, surgical removal of the nail [5]. However, oral medications carry a higher risk of systemic side effects compared to topical treatments [5].